A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

A study published in NPJ Vaccines looks at adjuvants in vaccines and their association with a lower risk of dementia. Dr Julia Dudley, Head of Research at Alzheimer’s Research UK, said: ...